This listing of claims will replace all prior versions, all listings, of claims in the application:

Listing of Claims:

Claims 1-9 (canceled)

Claim 10 (currently amended): An implant for controlled, sustained drug release comprising:

a pharmacologically acceptable biodegradable polymer which is degraded at the site of implantation, wherein said biodegradable polymer comprises at least about 20 weight percent of the implant;

a first therapeutically active agent at a concentration from 10 to 50 weight percent of the implant;

a release modulator comprising hydroxypropylmethylcellulose at a concentration from 10 to 50 weight percent of the implant, and said release modulator further comprising a second therapeutically active agent;

wherein ~~said ipmlant~~ said implant is an anhydrous solid structure which is degraded at the site of implantation and releases said first therapeutically active agent within a therapeutic dosage which does not vary by more than about 100% for a period of at least about 3 days after implantation.

Claims 11-12 (canceled)

Claim 13 (previously presented): An implant according to claim 10, wherein said anhydrous solid structure is a particle, sheet, plaque, fiber, microcapsule, microsphere or disc.

Claim 14-15 (canceled)

Claim 16 (currently amended): An implant ~~according to claim 15~~ according to claim 10, wherein said first therapeutically active agent is a steroid and said second therapeutically active agent is a water soluble antibiotic.

Claim 17 (currently amended): An implant ~~according to claim 15~~ according to claim 10, wherein said first therapeutically active agent is a non-steroidal antiinflammatory drug and said second therapeutically active agent is a water soluble antibiotic.

Claim 18 (previously presented): An implant according to claim 10 wherein said biodegradable polymer is poly-lactate glycolate acid copolymer.

Claim 19 (previously presented): An implant for controlled, sustained drug release comprising:

poly-lactate glycolic acid copolymer at a concentration of at least about 20 weight percent of the implant;

a therapeutically active antiinflammatory drug at a concentration from 10 to 50 weight percent of the implant;

a release modulator comprising hydroxy-propylmethylcellulose at a concentration from 10 to 50 weight percent of the implant;

wherein said implant is an anhydrous solid structure which releases said therapeutically active antiinflammatory within a therapeutic dosage that does not vary by more than about 100% for a period of at least about 3 days.

Claim 20 (previously presented): An implant for controlled,

sustained drug release comprising:

poly-lactate glycolic acid copolymer at a concentration of at least about 20 weight percent of the implant;

a therapeutically active steroid at a concentration from 10 to 50 weight percent of the implant;

a release modulator comprising hydroxy-propylmethylcellulose at a concentration from 10 to 50 weight percent of the implant;

wherein said implant is an anhydrous solid structure which is degraded at the site of implantation and releases said therapeutically active steroid within a therapeutic dosage which does not vary by more than about 100% for a period of at least about 3 days after implantation.

Claim 21 (canceled)

Claim 22 (previously presented): An implant according to claim 20, wherein said anhydrous solid structure is a particle, sheet, patch, plaque, fiber, microcapsule, microsphere or disc.

Claim 23 (previously presented): An implant according to claim 20 wherein said release modulator further comprises a second therapeutically active agent.

Claim 24 (previously presented): An implant according to claim 23 wherein said second therapeutically active agent is a water soluble antibiotic.

Claim 25 (previously presented): A implant for controlled, sustained drug release comprising:

poly-lactate glycolic acid copolymer at a concentration

of at least about 20 weight percent of the implant;

a therapeutically active non-steroidal antiinflammatory drug at a concentration from 10 to 50 weight percent of the implant;

a release modulator comprising hydroxypropylmethylcellulose at a concentration from 10 to 50 weight percent of the implant;

wherein said implant is an anhydrous solid structure which releases said therapeutically active non-steroidal antiinflammatory drug within a therapeutic dosage which does not vary by more than about 100% for a period of at least about 3 days after implantation.

Claim 26-27 (canceled)

Claim 28 (previously presented): An implant according to claim 25, wherein said release modulator further comprises a second therapeutically active agent.

Claim 29 (previously presented): An implant according to claim 28, wherein said second therapeutically active agent is a water soluble antibiotic.

Claims 30-43 (canceled)